Financial Performance - The company reported a basic earnings per share of -0.6700 yuan for 2024, an improvement of 5.63% compared to -0.7100 yuan in 2023 [1] - The total revenue decreased significantly to 1.79 billion yuan, down 34.67% from 2.74 billion yuan in the previous year [1] - The net profit for 2024 was -1.27 billion yuan, showing a slight improvement from -1.37 billion yuan in 2023, reflecting a 7.3% increase [1] - The return on equity was -3.42%, slightly worse than -3.41% in 2023 [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 86.6999 million shares, accounting for 45.11% of the circulating shares, with a change of 0.9446 million shares from the previous period [2] - Shanghai Zhijiang Pharmaceutical Co., Ltd. remains the largest shareholder with 64.9696 million shares, representing 33.81% of the total share capital [3] - The fund "Guangfa Value Core Mixed A" increased its holdings by 1.2840 million shares, now holding 4.8172 million shares, which is 2.51% of the total [3] Dividend Distribution - The company has decided not to distribute dividends or increase capital [3]
之江生物:2024年报净利润-1.27亿 同比增长7.3%